Mia Petljak
@MPetljak
Assistant Prof @nyugrossman @Perlmutter_CC | Somatic mosaicism in cancer & aging 💻🔬 Opinions my own. Also at: https://bsky.app/profile/miapetljak.bsky.social
🚨OPEN POSTDOC POSITION in our brand new lab space by Madison Sq NYC ! 🌆🧬🔬 Do experiments, learn computation, and uncover drivers of a major mutational process affecting >50% of cancers, driving therapy resistance & impacting immunotherapy responses👇 med.nyu.edu/research/postd…
Some trully trainee led science! @Elsa2Bernard @oriol_pich Maria Zagorulya - our work is done here! Read how CH can influence solid tumor progression & treatment response ⬇️ @NEJM with the one & only @CharlesSwanton @MSKCancerCenter @TheCrick
🚨Thrilled to share our latest work: “Tumor-Infiltrating Clonal Hematopoiesis” @NEJM - we investigated how age-related blood mutations impact cancer when they infiltrate tumors, with @Elsa2Bernard Maria Zagorulya, @PapaemmanuilLab @CharlesSwanton + more nejm.org/doi/full/10.10…
Excited to share our exploration @naturemethods into new horizons opening up in the era of low cost sequencing! 🔥 Deeper sequencing at WGS scale for PPM sensitivity of tumor informed MRD 🔥Duplex sequencing at WGS scale for plasma only exploration of ctDNA Check out thread 👇
What happens when sequencing costs go ⏬ ? Imagination and new opportunities go ⏫ @landau_lab Let's look at what you can do when you perform deep WGS on cfDNA for cancer detection. Our recent work with the @UltimaGenomics platform 🧵👇 Lets goooo!! rdcu.be/ehkUb
Big moment for the lab—officially welcoming Fiona — our first PhD student! ⭐️🎉 Mentorship is one of the most rewarding parts of this job, and I can’t wait for us to embark on the first of many PhD journeys ahead 🤗
Transitioning to BlueSky (late to the party…..!) Find me at: bsky.app/profile/miapet…
#mRNAvaccines for #PancreaticCancer (PDAC) PART4 1. Out today in @Nature nature.com/articles/s4158… 🧵👇🏽 [1/23]
Our paper on Ultra-Rapid ddPCR (15 min tissue to result somatic mutation quantification) is now in @MedCellPress. A wonderful collaboration with @DanOrringerMD that succeeded because of the intrepid work of @ZacharyR_Murphy, Emilia Bianchini, and the team. cell.com/med/abstract/S…
👇breakthrough - non-opioid pain signaling inhibitor & first approved new class of pain medicine in >20 yrs 😮👏
#Breaking: The U.S. FDA approves our treatment for moderate-to-severe acute pain in adults. This is the first new class of pain medicine to be approved in over 20 years. Learn more: news.vrtx.com/news-releases/…
1/ Introducing SCimilarity, a new foundation model to explore scRNAseq data across tissues and diseases! It learns a common measure of cell similarity by training a deep metric learning model on millions of cells from various human tissues and conditions. nature.com/articles/s4158…
Excited to share our latest work. We introduce an improved version of NanoSeq, a duplex sequencing protocol with <5 errors per billion bp in single DNA molecules, and use it to study the somatic mutation landscape of oral epithelium in >1000 people. 1/n medrxiv.org/content/10.110…
It was a great pleasure to discuss advances in human genetics & genomics last week in Beijing with great colleagues, fantastic hosts & over the best food, sights and most inspiring research 🧬💕
Excited to see Ben Ebert as the new CEO at DFCI! His brilliance is matched only by his compassion and humanity. Ben’s been a fantastic collaborator and advisor to so many of us. Looking forward to witnessing all that’s ahead under his leadership.
Dr. Laurie Glimcher, CEO of Dana-Farber Cancer Institute, said she would step down next month. Dr. Benjamin Ebert, chair of Dana-Farber’s medical oncology department, will take over on Oct. 1. trib.al/WVBqnUH
Wow!
Exciting new inroads into human biology and therapy development: Human intestinal organoids with an autologous tissue-resident immune compartment! #Gjorevski #Cabon #IHB @Nature @IHB_Research nature.com/articles/s4158…
Paper out!📢 @AnupriyaSingha9 and #HannahStyers from the lab find acute resistance to targeting KRAS in pancreas cancer is surprisingly driven by a classical epithelial state. Co-targeting classical cells and KRAS augments response - clinically important! aacrjournals.org/cancerdiscover…
Now out @Nature, our paper on HiDEF-seq: single-molecule DNA sequencing that resolves single-strand changes (mismatches and damage)! go.nature.com/3KG7Njh
Clustered mutations occur more frequently than expected, and translesion synthesis (TLS) drives collateral mutagenesis on both the leading and lagging strands. SNVs are clustered downstream of deletions (biased towards deletion of T) but upstream of insertions. [4/13]
From a single member in Aug 2023 to this powerhouse squad! 🚀 💕#BestTeam
